The Department of Health and Human Services's NAICS 541714 (Research and Development in Biotechnology (except Nanobiotechnology)) market: incumbents, spending trend, set-asides and open solicitations — from FY2026 USAspending awards and live SAM.gov notices.
Contract data as of Oct 18, 2026 (USAspending) · recent coverage verified weekly
| Quarter | Awards | Obligated | Change |
|---|---|---|---|
| Q1 FY2026 | 10 | $17.1M | — |
| Q2 FY2026 | 8 | $1.2M | -93% |
| Q3 FY2026 | 14 | $457.3M | +38862% |
| Q4 FY2026 | 76 | $164.3M | -64% |
Federal fiscal quarters (Q1 = Oct–Dec). Awards are counted in the quarter they start; obligations are the award's obligated amount.
| # | Contractor | Obligated | Share |
|---|---|---|---|
| 1 | ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) | $263.6M | 41.2% |
| 2 | SHIONOGI & COMPANY LIMITED | $156.1M | 24.4% |
| 3 | KALEO, INC. | $96.1M | 15.0% |
| 4 | VERICEL CORPORATION | $34.9M | 5.5% |
| 5 | OXOS MEDICAL INC | $9.6M | 1.5% |
Registrations are rolled up to their corporate parent (USAspending parent UEI), so a company with several SAM registrations ranks once.
| Set-aside type | Obligated | Share |
|---|---|---|
| Small business set-aside | $50K | 0.0% |
| 8(a) | $0 | 0.0% |
| SDVOSB | $0 | 0.0% |
| WOSB / EDWOSB | $0 | 0.0% |
| HUBZone | $0 | 0.0% |
| No set-aside (full & open) | $612.9M | 100.0% |
Share of obligations on awards whose set-aside type is recorded — 96% of this market's dollars. Most USAspending bulk-archive records leave the field blank, so blank awards are excluded rather than counted as full & open.
Showing the 10 most recently posted of 68. Links open the notice on SAM.gov.
Source: USAspending.gov contract awards (prime awards with a start date from Oct 1, 2025 through Sep 30, 2026), SAM.gov contract opportunities, and SBA size standards. Recompetes are contracts whose final end date — options included — falls in the next 12 months. Figures are recomputed when a new USAspending load lands. See our data sources.